[MO-88] 2-Years Clinical Outcomes between Drug Coated Stent and the Second-Generation Bare Nitinol Stent for de novo Femoropopliteal Lesions
Backgrounds
Endovascular treatment (EVT) is effective for femoropopliteal (FP) lesions. However, for complex lesions, the clinical outcomes of EVT using bare nitinol stent (BNS) has not been sufficient. The effectiveness of drug coated stent (DCS) has been reported by some clinical trials. However, the effectiveness of DCS is little known compared to BNS in Japan.
Methods
Consecutive 118 patients, 129 de novo FP lesions treated with the second-generation BNS or DCS were retrospectively enrolled from our single center database. 58 patients with 63 lesions were treated by using BNS and 60 Patients, 66 lesions were treated with DCS. Primary endpoint was primary patency defined as peak systolic velocity ratio > 2.4 by duplex ultrasound.
Results
Patients and lesions characteristics were shown in the table. At 2 years, the primary patency of DCS was 74.2%, while it was 54.0% for the second-generation BNS (p=0.026, See Figure).
Conclusions
For de novo FP lesions, DCS is significantly superior to the second-generation BNS at 2 years.
Endovascular treatment (EVT) is effective for femoropopliteal (FP) lesions. However, for complex lesions, the clinical outcomes of EVT using bare nitinol stent (BNS) has not been sufficient. The effectiveness of drug coated stent (DCS) has been reported by some clinical trials. However, the effectiveness of DCS is little known compared to BNS in Japan.
Methods
Consecutive 118 patients, 129 de novo FP lesions treated with the second-generation BNS or DCS were retrospectively enrolled from our single center database. 58 patients with 63 lesions were treated by using BNS and 60 Patients, 66 lesions were treated with DCS. Primary endpoint was primary patency defined as peak systolic velocity ratio > 2.4 by duplex ultrasound.
Results
Patients and lesions characteristics were shown in the table. At 2 years, the primary patency of DCS was 74.2%, while it was 54.0% for the second-generation BNS (p=0.026, See Figure).
Conclusions
For de novo FP lesions, DCS is significantly superior to the second-generation BNS at 2 years.